ReviewMayo Clinic proceedings2024
Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.
Review in Mayo Clinic proceedings, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Towards reliable morphological subtyping and cancer detection on Barrett's esophagus pathology through ensembling foundation models.NPJ digital medicine · 2026Article
- Evaluating ChatGPT-5 for Detection of Barrett's Esophagus and Grading of Esophagitis: A Multiclass Endoscopic Image Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Alcohol Consumption and Age-Specific Risk of Esophageal Cancer: Prospective Cohort Study.JMIR public health and surveillance · 2026Article
- Screening for Barrett's esophagus and esophageal adenocarcinoma: recent advances and next steps.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Review
- Assessing the Relationship Between Steatotic Liver Disease and Barrett's Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants.Zeitschrift fur Gastroenterologie · 2026Article
- A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.Current gastroenterology reports · 2026Review
- Endoscopic Screening of Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026Review
- Current Concepts for Diagnosing Non-Dysplastic and Dysplastic Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026Review
- Strategies to prevent Barrett's esophagus associated esophageal adenocarcinoma.World journal of gastroenterology · 2025Review
- Future of image enhanced endoscopy of esophageal adenocarcinoma.Clinical endoscopy · 2025Review
- Gender disparities and woman-specific trends in Barrett's esophagus in the United States: An 11-year nationwide population-based study.World journal of methodology · 2025Article
- Current status and perspectives of esophageal cancer: a comprehensive review.Cancer communications (London, England) · 2025Review
- Review
- The Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.Journal of cancer science and clinical therapeutics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Esophageal adenocarcinoma (EAC), the primary form of esophageal cancer in the United States, is a lethal cancer with exponentially increasing incidence. Screening for Barrett esophagus (BE), the only known precursor to EAC, followed by endoscopic surveillance to detect dysplasia and early-stage EAC and subsequent endoscopic treatment (to prevent progression of dysplasia to EAC and to treat early-stage EAC effectively) is recommended by several society guidelines. Sedated endoscopy (the primary current tool for BE screening) is both invasive and expensive, limiting its widespread use. In this review, we aim to provide a comprehensive review of recent innovations in the nonendoscopic detection of BE and EAC. These include swallowable cell sampling devices combined with protein and epigenetic biomarkers (which are now guideline endorsed as alternatives to sedated endoscopy), tethered capsule endomicroscopy, emerging peripheral blood-sampled molecular biomarkers, and exhaled volatile organic compounds. We also summarize progress and challenges in assessing BE and EAC risk, which is an important complementary component of the process for the clinical implementation of these innovative nonendoscopic tools, and propose a new paradigm for the strategy to reduce EAC incidence and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.